数千万A+轮融资！聚焦肿瘤介入治疗器械国产创新

Core Viewpoint - Meidida Medical, focused on tumor interventional therapy, has completed a multi-million A+ round financing to accelerate the development and clinical promotion of innovative medical devices for tumor treatment [2][15]. Industry Background - Tumor interventional therapy is gaining clinical attention due to its minimally invasive and precise nature, with techniques like thermal ablation becoming important alternatives for solid tumors such as liver, lung, and kidney cancers [3]. - Microwave ablation (MWA) is a mature thermal ablation method that uses microwave energy to induce heat in tumor tissues, leading to coagulative necrosis, particularly suitable for patients who cannot tolerate surgery. MWA offers advantages over traditional radiofrequency ablation, including faster heating, larger ablation areas, and reduced thermal loss [3]. Company Introduction - Meidida Medical is a high-tech medical company specializing in the research and industrialization of tumor interventional therapy devices, aiming to address clinical safety, efficiency, and complication risks associated with traditional techniques [6]. Core Products and Technology Introduction - The coaxial puncture thermal coagulation needle integrates biopsy and hemostasis in one device, significantly reducing bleeding risks and complications while enhancing operational safety and reducing post-operative care costs. This product is expected to enter the innovative channel for rapid registration and market launch by 2025 [9][10]. - The 5.8GHz high-frequency microwave ablation needle, recognized in Shanghai's "New and Excellent Drug and Device" catalog, offers faster energy transmission and better control over the ablation area compared to traditional systems. This positions Meidida Medical's platform as a competitive solution for treating various solid tumors, with significant potential to replace imported devices in the domestic market [13][14]. Conclusion - As minimally invasive tumor treatment becomes mainstream, domestic interventional device manufacturers like Meidida Medical are expected to reduce reliance on imports, lower patient costs, and improve clinical accessibility. The recent financing will accelerate the company's technology transfer and industrialization process, marking a new development phase for domestic tumor interventional devices [15].